Get the Stockscreener App
29.76
4.03%
-1.25
Pre-market:
29.93
0.17
+0.57%
Omnicell Inc stock is traded at $29.76, with a volume of 742.47K.
It is down -4.03% in the last 24 hours and down -0.57% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
See More
Previous Close:
$31.01
Open:
$30.72
24h Volume:
742.47K
Relative Volume:
1.21
Market Cap:
$1.39B
Revenue:
$1.08B
Net Income/Loss:
$-20.76M
P/E Ratio:
-64.70
EPS:
-0.46
Net Cash Flow:
$151.63M
1W Performance:
+5.27%
1M Performance:
-0.57%
6M Performance:
-33.85%
1Y Performance:
-23.40%
1-Day Range:
$29.51
$30.89
1-Week Range:
$28.09
$33.99
52-Week Range:
$22.66
$55.74
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
29.76 | 1.45B | 1.08B | -20.76M | 151.63M | -0.46 |
|
VEEV
Veeva Systems Inc
|
281.35 | 46.44B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
54.89 | 9.80B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
91.06 | 8.39B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
57.33 | 11.01B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
35.59 | 6.44B | 906.14M | -52.62M | 89.62M | -0.3621 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
What is Omnicell Inc. company’s growth strategyMaximize gains with proven stock analysis - jammulinksnews.com
What analysts say about Omnicell Inc. stockMassive profits - jammulinksnews.com
Omnicell Inc. Stock Analysis and ForecastInvest smarter with actionable market insights - jammulinksnews.com
What are the latest earnings results for Omnicell Inc.Get insider insights into market trends - jammulinksnews.com
Is Omnicell Inc. a growth stock or a value stockAchieve consistent profits with expert strategies - jammulinksnews.com
When is Omnicell Inc. stock expected to show significant growthBuild a portfolio for long-term financial success - jammulinksnews.com
Is it the right time to buy Omnicell Inc. stockInvest smarter with actionable trading signals - jammulinksnews.com
How does Omnicell Inc. compare to its industry peersDouble-digit growth - jammulinksnews.com
Why is Omnicell Inc. stock attracting strong analyst attentionTremendous return rates - jammulinksnews.com
What is the dividend policy of Omnicell Inc. stockCapitalize on emerging investment opportunities - jammulinksnews.com
What markets is SEAL.PRB expanding into Is Omnicell Inc. stock a good long term investment optionAchieve consistent high returns with low risk - jammulinksnews.com
How strong is Omnicell Inc. company’s balance sheetExceptional financial outcomes - jammulinksnews.com
Omnicell's Q2 2025 Earnings Highlight Resilience and Growth in Healthcare Automation - AInvest
Omnicell's Q2 2025 Earnings Outperformance: A Strategic Case for Capitalizing on a Resilient Medical Tech Innovator - AInvest
Omnicell Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Omnicell's Financial Performance and Growth Prospects Support Buy Rating - AInvest
Omnicell's Strategic Shift to Recurring Revenue: A Pathway to Sustainable Growth in 2025 - AInvest
Omnicell's Q2 2025 Earnings and Strategic Edge in the Autonomous Pharmacy Market: A Case for Long-Term Growth - AInvest
Omnicell, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:OMCL) - Seeking Alpha
Pharmacy Automation Market: Strategic Growth, Competitive Landscape & Long-Term Value for Healthcare Leaders - Barchart.com
What are analysts’ price targets for Omnicell Inc. in the next 12 monthsExpert Picks Outlook From AI Tools - jammulinksnews.com
Wall Street Analysts See a 44.47% Upside in Omnicell (OMCL): Can the Stock Really Move This High? - Yahoo Finance
Omnicell outlines $40M tariff impact and anticipates $1.105B-$1.155B revenue for 2025 - MSN
Omnicell: Q2 Earnings Snapshot - Norwalk Hour
PSI Software Q2 2025 Earnings: €0.11 loss per share, up 73% from Q2 2024; revenue increases 18% to €73.0m. - AInvest
Omnicell Raises Guidance After Outpacing Analyst Expectations - Finimize
Omnicell Q2 Earnings: Market Ignoring The Segments (NASDAQ:OMCL) - Seeking Alpha
Earnings call transcript: Omnicell Q2 2025 beats expectations with strong earnings By Investing.com - Investing.com South Africa
Earnings call transcript: Omnicell Q2 2025 beats expectations with strong earnings - Investing.com
Omnicell Shares Marginally Higher After Reporting Fall in Q2 Earnings, Higher Revenue - 富途牛牛
Omnicell Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Omnicell Shares Climb Over 2% After Second Quarter Results Surpass Expectations - MSN
Omnicell Q2 2025 slides: Revenue up 5%, shares jump on recurring revenue growth - Investing.com Australia
Omnicell Q2 2025 slides: Revenue up 5%, shares jump on recurring revenue growth By Investing.com - Investing.com South Africa
Omnicell's Strategic Momentum and Earnings Outperformance: A Case for Upside in Automated Healthcare Solutions - AInvest
Omnicell (OMCL) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Omnicell Announces Second Quarter 2025 Results | OMCL Stock News - GuruFocus
Omnicell shares rise over 2% as second quarter results exceed expectations - Investing.com Nigeria
Omnicell (NASDAQ:OMCL) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
OMNICELL Earnings Results: $OMCL Reports Quarterly Earnings - Quiver Quantitative
Omnicell Announces Strong Q2 2025 Financial Results - TradingView
Omnicell Announces Second Quarter 2025 Results - Yahoo Finance
Intrinsic Value of Omnicell Inc. Stock: Is It Undervalued or OvervaluedQuick Gain Stock Watch With Indicators Reviewed - beatles.ru
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omnicell Inc Stock (OMCL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PARRISH MARK W | Director |
Dec 10 '24 |
Sale |
47.30 |
12,000 |
567,638 |
58,427 |
0.98%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):